Europe Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity

August 2020 | 123 pages | ID: E7F1816C6746EN
GMD Research

Abstracts

Europe antibiotics market accounted for $11.65 billion in 2019 and will grow by 3.4% annually over 2020-2030 owing to the rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic.

Highlighted with 35 tables and 59 figures, this 123-page report “Europe Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country.

Based on Drug Class, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Cephalosporin
• Penicillin
• Macrolides
• Fluoroquinolones
• Quinolones
• Monobactam
• Aminoglycosides
• Carbapenem
• Other Drug Classes

Based on Action Mechanism, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Cell Wall Synthesis Inhibitors
• Mycolic Acid Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Protein Synthesis Inhibitors
• Other Mechanisms

Based on Drug Origin, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Natural Antibiotics
• Semi-synthetic Antibiotics
• Synthetic Antibiotics

Based on Activity Spectrum, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Broad-spectrum Antibiotics
• Narrow-spectrum Antibiotics

Based on Route of Administration, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Oral Administration
• Intravenous Administration
• Other Administration Routes

Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Brand Antibiotics
• Generic Antibiotics

Geographically, the following national/local markets are fully investigated:

• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF EUROPE MARKET BY DRUG CLASS

3.1 Market Overview by Drug Class
3.2 Cephalosporin
3.3 Penicillin
3.4 Macrolides
3.5 Fluoroquinolones
3.6 Quinolones
3.7 Monobactam
3.8 Aminoglycosides
3.9 Carbapenem
3.10 Other Drug Classes

4 SEGMENTATION OF EUROPE MARKET BY ACTION MECHANISM

4.1 Market Overview by Action Mechanism
4.2 Cell Wall Synthesis Inhibitors
4.3 Mycolic Acid Inhibitors
4.4 RNA Synthesis Inhibitors
4.5 DNA Synthesis Inhibitors
4.6 Protein Synthesis Inhibitors
4.7 Other Mechanisms

5 SEGMENTATION OF EUROPE MARKET BY DRUG ORIGIN

5.1 Market Overview by Drug Origin
5.2 Natural Antibiotics
5.3 Semi-synthetic Antibiotics
5.4 Synthetic Antibiotics

6 SEGMENTATION OF EUROPE MARKET BY ACTIVITY SPECTRUM

6.1 Market Overview by Activity Spectrum
6.2 Broad-spectrum Antibiotics
6.3 Narrow-spectrum Antibiotics

7 SEGMENTATION OF EUROPE MARKET BY ROUTE OF ADMINISTRATION

7.1 Market Overview by Route of Administration
7.2 Oral Administration
7.3 Intravenous Administration
7.4 Other Administration Routes

8 SEGMENTATION OF EUROPE MARKET BY DRUG TYPE

8.1 Market Overview by Drug Type
8.2 Brand Antibiotics
8.3 Generic Antibiotics

9 EUROPEAN MARKET 2019-2030 BY COUNTRY

9.1 Overview of European Market
9.2 Germany
9.3 UK
9.4 France
9.5 Spain
9.6 Italy
9.7 Russia
9.8 Rest of European Market

10 COMPETITIVE LANDSCAPE

10.1 Overview of Key Vendors
10.2 New Product Launch, Partnership, Investment, and M&A
10.3 Company Profiles
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.

11 INVESTING IN EUROPE MARKET: RISK ASSESSMENT AND MANAGEMENT

11.1 Risk Evaluation of Europe Market
11.2 Critical Success Factors (CSFs)
Related Reports and Products

List Of Tables

LIST OF TABLES

Table 1. Snapshot of Europe Antibiotics Market, 2019-2030
Table 2. Main Product Trends and Market Opportunities in Europe Antibiotics Market
Table 3. Europe Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 4. Europe Antibiotics Market by Action Mechanism, 2019-2030, $ mn
Table 5. Europe Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 6. Europe Antibiotics Market by Activity Spectrum, 2019-2030, $ mn
Table 7. Europe Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 8. Europe Antibiotics Market by Drug Type, 2019-2030, $ bn
Table 9. Europe Antibiotics Market by Country, 2019-2030, $ bn
Table 10. Germany Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 11. Germany Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 12. Germany Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 13. UK Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 14. UK Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 15. UK Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 16. France Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 17. France Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 18. France Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 19. Spain Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 20. Spain Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 21. Spain Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 22. Italy Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 23. Italy Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 24. Italy Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 25. Russia Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 26. Russia Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 27. Russia Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 28. Antibiotics Market in Rest of Europe by Country, 2019-2030, $ bn
Table 29. Abbott Laboratories: Company Snapshot
Table 30. Abbott Laboratories: Business Segmentation
Table 31. Abbott Laboratories: Product Portfolio
Table 32. Abbott Laboratories: Revenue, 2016-2018, $ mn
Table 33. Abbott Laboratories: Recent Developments
Table 34. Risk Evaluation for Investing in Europe Market, 2019-2030
Table 35. Critical Success Factors and Key Takeaways

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Europe Antibiotics Market, 2019-2030, $ mn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Europe Antibiotics Market
Figure 8. GDP per capita in the World, 1960-2018, $ thousand
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million
Figure 10. Primary Restraints and Impact Factors of Europe Antibiotics Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of Europe Antibiotics Market
Figure 13. Breakdown of Europe Antibiotics Market by Drug Class, 2019-2030, % of Revenue
Figure 14. Europe Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%)
Figure 15. Europe Antibiotics Market: Cephalosporin, 2019-2030, $ mn
Figure 16. Europe Antibiotics Market: Penicillin, 2019-2030, $ mn
Figure 17. Europe Antibiotics Market: Macrolides, 2019-2030, $ mn
Figure 18. Europe Antibiotics Market: Fluoroquinolones, 2019-2030, $ mn
Figure 19. Europe Antibiotics Market: Quinolones, 2019-2030, $ mn
Figure 20. Europe Antibiotics Market: Monobactam, 2019-2030, $ mn
Figure 21. Europe Antibiotics Market: Aminoglycosides, 2019-2030, $ mn
Figure 22. Europe Antibiotics Market: Carbapenem, 2019-2030, $ mn
Figure 23. Europe Antibiotics Market: Other Drug Classes, 2019-2030, $ mn
Figure 24. Breakdown of Europe Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue
Figure 25. Europe Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%)
Figure 26. Europe Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn
Figure 27. Europe Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn
Figure 28. Europe Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn
Figure 29. Europe Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn
Figure 30. Europe Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn
Figure 31. Europe Antibiotics Market: Other Mechanisms, 2019-2030, $ mn
Figure 32. Breakdown of Europe Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue
Figure 33. Europe Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%)
Figure 34. Europe Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn
Figure 35. Europe Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn
Figure 36. Europe Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn
Figure 37. Breakdown of Europe Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue
Figure 38. Europe Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%)
Figure 39. Europe Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn
Figure 40. Europe Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn
Figure 41. Breakdown of Europe Antibiotics Market by Route of Administration, 2019-2030, % of Revenue
Figure 42. Europe Addressable Market Cap in 2020-2030 by Route of Administration, Value ($ mn) and Share (%)
Figure 43. Europe Antibiotics Market: Oral Administration, 2019-2030, $ mn
Figure 44. Europe Antibiotics Market: Intravenous Administration, 2019-2030, $ mn
Figure 45. Europe Antibiotics Market: Other Administration Routes, 2019-2030, $ mn
Figure 46. Breakdown of Europe Antibiotics Market by Drug Type, 2019-2030, % of Revenue
Figure 47. Europe Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%)
Figure 48. Europe Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn
Figure 49. Europe Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn
Figure 50. Breakdown of European Antibiotics Market by Country, 2019 and 2030, % of Revenue
Figure 51. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 52. Antibiotics Market in Germany, 2019-2030, $ bn
Figure 53. Antibiotics Market in UK, 2019-2030, $ bn
Figure 54. Antibiotics Market in France, 2019-2030, $ bn
Figure 55. Antibiotics Market in Spain, 2019-2030, $ bn
Figure 56. Antibiotics Market in Italy, 2019-2030, $ bn
Figure 57. Antibiotics Market in Russia, 2019-2030, $ bn
Figure 58. Antibiotics Market in Rest of Europe, 2019-2030, $ bn
Figure 59. Growth Stage of Europe Antibiotics Industry over the Forecast Period

COMPANIES MENTIONED

Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.